Dec 27, 2025 • MarketBeat
NEUTRAL
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC reduced its stake in BioCryst Pharmaceuticals (NASDAQ: BCRX) by 8.7%, selling 179,891 shares and ending the quarter with 1,880,389 shares valued at approximately $14.27 million. This move occurred amidst recent insider selling and while analysts maintain a "Moderate Buy" rating for BCRX with an average target price of $19.50. The biotechnology company, which reported a 36.1% year-over-year revenue increase, currently trades near $7.63.
Dec 25, 2025 • Stock Traders Daily
NEUTRAL
Price-Driven Insight from (BCRX) for Rule-Based Strategy
This article provides a price-driven analysis for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), outlining institutional trading strategies based on AI models. It highlights a strong near-term sentiment that could influence neutral mid and long-term outlooks, and identifies specific entry, target, and stop-loss zones for long, momentum breakout, and short positions. The analysis also emphasizes an exceptional risk-reward short setup for BCRX.
Dec 23, 2025 • TipRanks
NEUTRAL
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger
Astria Therapeutics is facing two shareholder lawsuits alleging misleading disclosures related to its planned merger with BioCryst Pharmaceuticals. Astria agreed to be acquired by BioCryst in October 2025, becoming a wholly-owned subsidiary. Despite the lawsuits, which Astria denies as meritless, the company plans to vigorously defend itself and move forward with the merger process.
Dec 23, 2025 • TradingView — Track All Markets
SOMEWHAT-BEARISH
Astria Therapeutics Merger with BioCryst Pharmaceuticals
Astria Therapeutics filed a definitive proxy statement on December 18, 2025, for its merger with BioCryst Pharmaceuticals, which would make Astria a wholly-owned subsidiary of BioCryst. The company plans to defend against litigation claims alleging a misleading registration statement. Stockholders are expected to vote on the merger proposals at a special meeting.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BEARISH
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock
Alane Barnes, an insider at BioCryst Pharmaceuticals (NASDAQ:BCRX), sold 21,773 shares of the company's stock on December 22nd at an average price of $7.65 per share, totaling $166,563.45. This transaction reduced her stake by 5.18% to 398,751 shares. The company's stock traded down 1.1% to $7.53, with a market capitalization of $1.59 billion, and analysts currently have a "Moderate Buy" rating with a consensus price target of $19.50.
Dec 21, 2025 • Insider Monkey
BULLISH
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30
H.C. Wainwright increased its price target for BioCryst Pharmaceuticals (BCRX) to $32 from $30, maintaining a Buy rating on the stock. This adjustment follows the FDA approval of Orladeyo, BioCryst's hereditary angioedema treatment, for pediatric patients aged two to twelve years. The approval of this oral prophylactic therapy for a younger patient population represents a significant factor for the positive rating update.